Susquehanna International Group
EIDX

Susquehanna International Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Susquehanna International Group’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-30,700
Closed -$4.04M – 13236
2020
Q4 		$4.04M Buy
30,700
+21,900
+249% +$1.94M ﹤0.01% 3789
2020
Q3 		$445K Sell
8,800
-14,300
-62% -$643K ﹤0.01% 7916
2020
Q2 		$1.1M Sell
23,100
-54,600
-70% -$2.54M ﹤0.01% 5700
2020
Q1 		$3.81M Sell
77,700
-78,100
-50% -$3.98M ﹤0.01% 2935
2019
Q4 		$8.94M Buy
+155,800
New +$7.71M ﹤0.01% 2208

Susquehanna International Group's EIDX Position: Q1 2021 in Review

Susquehanna International Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 4,560 shares — an estimated $600K sold.

Susquehanna International Group first reported a position in EIDX in Q3 2018 and held it in 6 quarters. The position peaked at $1.93M in Q2 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Susquehanna International Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Susquehanna International Group sold 4,560 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $600K.
  • Susquehanna International Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 6 quarters.
  • Susquehanna International Group's Eidos Therapeutics, Inc. Common Stock position peaked at $1.93M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Susquehanna International Group's 13F filing for Q1 2021, filed 17 May 2021.